Novo Nordisk A/S (XETRA: NOVC.DE) Stock Competitors & Peer Comparison
See NOVC.DE's competitors and their performance on the XETRA and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for NOVC.DE and its XETRA peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NOVC.DE | €91.40 | -2.42% | 406.7B | 22.91 | €3.99 | +12.20% |
| LLY.DE | €996.20 | -0.20% | 942.9B | 37.84 | €26.46 | +0.57% |
| JNJ.DE | €235.35 | +0.53% | 566.3B | 26.37 | €8.91 | +1.93% |
| 4AB.DE | €228.20 | -0.31% | 407.8B | 40.41 | €5.71 | +2.53% |
| 4AB.DU | €227.70 | -1.00% | 404.8B | 40.12 | €5.71 | +2.55% |
| 6MK.DE | €128.08 | +0.00% | 315.5B | 51.13 | €2.50 | +2.30% |
| ZEG.DE | €160.70 | +0.59% | 249.2B | 26.61 | €6.04 | +1.72% |
| AMG.DE | €336.35 | +3.21% | 179.3B | 17.23 | €19.28 | +2.56% |
| NOV.DE | €36.02 | -4.67% | 167.1B | 12.05 | €3.12 | +4.13% |
| GIS.DE | €130.42 | +0.43% | 162.9B | -105.77 | -€1.24 | +2.14% |
Stock Comparison
Eli Lilly and Company (XETRA: LLY.DE)
NOVC.DE vs LLY.DE Comparison September 2026
Novo Nordisk A/S (XETRA: NOVC.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVC.DE stands at 406.7B. In comparison, LLY.DE has a market cap of 942.9B. Regarding current trading prices, NOVC.DE is priced at €91.40 on the XETRA, while LLY.DE trades at €996.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVC.DE currently has a P/E ratio of 22.91, whereas LLY.DE's P/E ratio is 37.84. In terms of profitability, NOVC.DE's ROE is +0.88%, compared to LLY.DE's ROE of +0.93%. Regarding short-term risk, NOVC.DE is more volatile compared to LLY.DE. This indicates higher risk in terms of short-term price fluctuations for NOVC.DE.Check LLY.DE's competition here
Johnson & Johnson (XETRA: JNJ.DE)
NOVC.DE vs JNJ.DE Comparison September 2026
Novo Nordisk A/S (XETRA: NOVC.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVC.DE stands at 406.7B. In comparison, JNJ.DE has a market cap of 566.3B. Regarding current trading prices, NOVC.DE is priced at €91.40 on the XETRA, while JNJ.DE trades at €235.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVC.DE currently has a P/E ratio of 22.91, whereas JNJ.DE's P/E ratio is 26.37. In terms of profitability, NOVC.DE's ROE is +0.88%, compared to JNJ.DE's ROE of +0.26%. Regarding short-term risk, NOVC.DE is more volatile compared to JNJ.DE. This indicates higher risk in terms of short-term price fluctuations for NOVC.DE.Check JNJ.DE's competition here
AbbVie Inc. (XETRA: 4AB.DE)
NOVC.DE vs 4AB.DE Comparison September 2026
Novo Nordisk A/S (XETRA: NOVC.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVC.DE stands at 406.7B. In comparison, 4AB.DE has a market cap of 407.8B. Regarding current trading prices, NOVC.DE is priced at €91.40 on the XETRA, while 4AB.DE trades at €228.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVC.DE currently has a P/E ratio of 22.91, whereas 4AB.DE's P/E ratio is 40.41. In terms of profitability, NOVC.DE's ROE is +0.88%, compared to 4AB.DE's ROE of -1.37%. Regarding short-term risk, NOVC.DE is more volatile compared to 4AB.DE. This indicates higher risk in terms of short-term price fluctuations for NOVC.DE.Check 4AB.DE's competition here
AbbVie Inc. (DUS: 4AB.DU)
NOVC.DE vs 4AB.DU Comparison September 2026
Novo Nordisk A/S (XETRA: NOVC.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVC.DE stands at 406.7B. In comparison, 4AB.DU has a market cap of 404.8B. Regarding current trading prices, NOVC.DE is priced at €91.40 on the XETRA, while 4AB.DU trades at €227.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVC.DE currently has a P/E ratio of 22.91, whereas 4AB.DU's P/E ratio is 40.12. In terms of profitability, NOVC.DE's ROE is +0.88%, compared to 4AB.DU's ROE of -1.37%. Regarding short-term risk, NOVC.DE is more volatile compared to 4AB.DU. This indicates higher risk in terms of short-term price fluctuations for NOVC.DE.Check 4AB.DU's competition here
Merck & Co., Inc. (XETRA: 6MK.DE)
NOVC.DE vs 6MK.DE Comparison September 2026
Novo Nordisk A/S (XETRA: NOVC.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVC.DE stands at 406.7B. In comparison, 6MK.DE has a market cap of 315.5B. Regarding current trading prices, NOVC.DE is priced at €91.40 on the XETRA, while 6MK.DE trades at €128.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVC.DE currently has a P/E ratio of 22.91, whereas 6MK.DE's P/E ratio is 51.13. In terms of profitability, NOVC.DE's ROE is +0.88%, compared to 6MK.DE's ROE of +0.07%. Regarding short-term risk, NOVC.DE is more volatile compared to 6MK.DE. This indicates higher risk in terms of short-term price fluctuations for NOVC.DE.Check 6MK.DE's competition here
AstraZeneca PLC (XETRA: ZEG.DE)
NOVC.DE vs ZEG.DE Comparison September 2026
Novo Nordisk A/S (XETRA: NOVC.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVC.DE stands at 406.7B. In comparison, ZEG.DE has a market cap of 249.2B. Regarding current trading prices, NOVC.DE is priced at €91.40 on the XETRA, while ZEG.DE trades at €160.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVC.DE currently has a P/E ratio of 22.91, whereas ZEG.DE's P/E ratio is 26.61. In terms of profitability, NOVC.DE's ROE is +0.88%, compared to ZEG.DE's ROE of +0.22%. Regarding short-term risk, NOVC.DE is more volatile compared to ZEG.DE. This indicates higher risk in terms of short-term price fluctuations for NOVC.DE.Check ZEG.DE's competition here
Amgen Inc. (XETRA: AMG.DE)
NOVC.DE vs AMG.DE Comparison September 2026
Novo Nordisk A/S (XETRA: NOVC.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVC.DE stands at 406.7B. In comparison, AMG.DE has a market cap of 179.3B. Regarding current trading prices, NOVC.DE is priced at €91.40 on the XETRA, while AMG.DE trades at €336.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVC.DE currently has a P/E ratio of 22.91, whereas AMG.DE's P/E ratio is 17.23. In terms of profitability, NOVC.DE's ROE is +0.88%, compared to AMG.DE's ROE of +0.89%. Regarding short-term risk, NOVC.DE is more volatile compared to AMG.DE. This indicates higher risk in terms of short-term price fluctuations for NOVC.DE.Check AMG.DE's competition here
Novo Nordisk A/S (XETRA: NOV.DE)
NOVC.DE vs NOV.DE Comparison September 2026
Novo Nordisk A/S (XETRA: NOVC.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVC.DE stands at 406.7B. In comparison, NOV.DE has a market cap of 167.1B. Regarding current trading prices, NOVC.DE is priced at €91.40 on the XETRA, while NOV.DE trades at €36.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVC.DE currently has a P/E ratio of 22.91, whereas NOV.DE's P/E ratio is 12.05. In terms of profitability, NOVC.DE's ROE is +0.88%, compared to NOV.DE's ROE of +0.59%. Regarding short-term risk, NOVC.DE is less volatile compared to NOV.DE. This indicates lower risk in terms of short-term price fluctuations for NOVC.DE.Check NOV.DE's competition here
Gilead Sciences, Inc. (XETRA: GIS.DE)
NOVC.DE vs GIS.DE Comparison September 2026
Novo Nordisk A/S (XETRA: NOVC.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVC.DE stands at 406.7B. In comparison, GIS.DE has a market cap of 162.9B. Regarding current trading prices, NOVC.DE is priced at €91.40 on the XETRA, while GIS.DE trades at €130.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVC.DE currently has a P/E ratio of 22.91, whereas GIS.DE's P/E ratio is -105.77. In terms of profitability, NOVC.DE's ROE is +0.88%, compared to GIS.DE's ROE of -0.16%. Regarding short-term risk, NOVC.DE is more volatile compared to GIS.DE. This indicates higher risk in terms of short-term price fluctuations for NOVC.DE.Check GIS.DE's competition here
Pfizer Inc. (XETRA: PFE.DE)
NOVC.DE vs PFE.DE Comparison September 2026
Novo Nordisk A/S (XETRA: NOVC.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVC.DE stands at 406.7B. In comparison, PFE.DE has a market cap of 136.6B. Regarding current trading prices, NOVC.DE is priced at €91.40 on the XETRA, while PFE.DE trades at €24.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVC.DE currently has a P/E ratio of 22.91, whereas PFE.DE's P/E ratio is 10.34. In terms of profitability, NOVC.DE's ROE is +0.88%, compared to PFE.DE's ROE of +0.05%. Regarding short-term risk, NOVC.DE is more volatile compared to PFE.DE. This indicates higher risk in terms of short-term price fluctuations for NOVC.DE.Check PFE.DE's competition here
Bristol-Myers Squibb Company (XETRA: BRM.DE)
NOVC.DE vs BRM.DE Comparison September 2026
Novo Nordisk A/S (XETRA: NOVC.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVC.DE stands at 406.7B. In comparison, BRM.DE has a market cap of 111.9B. Regarding current trading prices, NOVC.DE is priced at €91.40 on the XETRA, while BRM.DE trades at €54.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVC.DE currently has a P/E ratio of 22.91, whereas BRM.DE's P/E ratio is 14.02. In terms of profitability, NOVC.DE's ROE is +0.88%, compared to BRM.DE's ROE of +0.47%. Regarding short-term risk, NOVC.DE is more volatile compared to BRM.DE. This indicates higher risk in terms of short-term price fluctuations for NOVC.DE.Check BRM.DE's competition here
Sanofi (XETRA: SNW.DE)
NOVC.DE vs SNW.DE Comparison September 2026
Novo Nordisk A/S (XETRA: NOVC.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVC.DE stands at 406.7B. In comparison, SNW.DE has a market cap of 89B. Regarding current trading prices, NOVC.DE is priced at €91.40 on the XETRA, while SNW.DE trades at €73.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVC.DE currently has a P/E ratio of 22.91, whereas SNW.DE's P/E ratio is 22.87. In terms of profitability, NOVC.DE's ROE is +0.88%, compared to SNW.DE's ROE of +0.09%. Regarding short-term risk, NOVC.DE is more volatile compared to SNW.DE. This indicates higher risk in terms of short-term price fluctuations for NOVC.DE.Check SNW.DE's competition here
Bayer Aktiengesellschaft (XETRA: BAYN.DE)
NOVC.DE vs BAYN.DE Comparison September 2026
Novo Nordisk A/S (XETRA: NOVC.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVC.DE stands at 406.7B. In comparison, BAYN.DE has a market cap of 47.2B. Regarding current trading prices, NOVC.DE is priced at €91.40 on the XETRA, while BAYN.DE trades at €48.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVC.DE currently has a P/E ratio of 22.91, whereas BAYN.DE's P/E ratio is 9.95. In terms of profitability, NOVC.DE's ROE is +0.88%, compared to BAYN.DE's ROE of -0.06%. Regarding short-term risk, NOVC.DE is more volatile compared to BAYN.DE. This indicates higher risk in terms of short-term price fluctuations for NOVC.DE.Check BAYN.DE's competition here
Bayer Aktiengesellschaft (STU: BAYN.SG)
NOVC.DE vs BAYN.SG Comparison September 2026
Novo Nordisk A/S (XETRA: NOVC.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVC.DE stands at 406.7B. In comparison, BAYN.SG has a market cap of 47.2B. Regarding current trading prices, NOVC.DE is priced at €91.40 on the XETRA, while BAYN.SG trades at €48.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVC.DE currently has a P/E ratio of 22.91, whereas BAYN.SG's P/E ratio is -42.09. In terms of profitability, NOVC.DE's ROE is +0.88%, compared to BAYN.SG's ROE of -0.06%. Regarding short-term risk, NOVC.DE is more volatile compared to BAYN.SG. This indicates higher risk in terms of short-term price fluctuations for NOVC.DE.Check BAYN.SG's competition here
Biogen Inc. (XETRA: IDP.DE)
NOVC.DE vs IDP.DE Comparison September 2026
Novo Nordisk A/S (XETRA: NOVC.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVC.DE stands at 406.7B. In comparison, IDP.DE has a market cap of 24.5B. Regarding current trading prices, NOVC.DE is priced at €91.40 on the XETRA, while IDP.DE trades at €165.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVC.DE currently has a P/E ratio of 22.91, whereas IDP.DE's P/E ratio is 14.83. In terms of profitability, NOVC.DE's ROE is +0.88%, compared to IDP.DE's ROE of +0.05%. Regarding short-term risk, NOVC.DE is less volatile compared to IDP.DE. This indicates lower risk in terms of short-term price fluctuations for NOVC.DE.Check IDP.DE's competition here
GSK plc (XETRA: GS7.DE)
NOVC.DE vs GS7.DE Comparison September 2026
Novo Nordisk A/S (XETRA: NOVC.DE) plays a significant role within the Healthcare sector. Its performance on the XETRA reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NOVC.DE stands at 406.7B. In comparison, GS7.DE has a market cap of 0. Regarding current trading prices, NOVC.DE is priced at €91.40 on the XETRA, while GS7.DE trades at €20.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NOVC.DE currently has a P/E ratio of 22.91, whereas GS7.DE's P/E ratio is 17.31. In terms of profitability, NOVC.DE's ROE is +0.88%, compared to GS7.DE's ROE of +0.26%. Regarding short-term risk, NOVC.DE is less volatile compared to GS7.DE. This indicates lower risk in terms of short-term price fluctuations for NOVC.DE.Check GS7.DE's competition here